John Herzog, MD
Cardiovascular Disease · Greenville, MSNPI 1093734949
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,395 of the $5,687 with a category attached, or 77.3%. 26 manufacturers reported payments, led by Medtronic at 24.7% of the total.
Across 139 payments — averaging $40.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Penumbra, Inc.$1K
- Cardiovascular Systems Inc.$683
- Abbott$351
- Terumo Medical Corporation$311
- AstraZeneca$266
- plus $1K from 20 others
What the payments were for
- Travel & lodging$1,21721%
- Food & beverage$4,39577%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 24 | $1,403 |
| Penumbra, Inc. | 13 | $1,358 |
| Cardiovascular Systems Inc. | 19 | $683 |
| Abbott | 16 | $351 |
| Terumo Medical Corporation | 6 | $311 |
| AstraZeneca | 10 | $266 |
| BD | 4 | $235 |
| Merck | 10 | $185 |
| Cvrx, Inc. | 3 | $104 |
| Philips North America LLC | 5 | $104 |
| Akebia Therapeutics Inc | 1 | $91 |
| Angiodynamics, Inc. | 2 | $90 |
| Boston Scientific | 2 | $72 |
| Novartis | 4 | $60 |
| Johnson & Johnson | 3 | $59 |
| Veryan Medical Incorporated | 1 | $54 |
| Bard Peripheral Vascular, Inc. | 2 | $48 |
| Boehringer Ingelheim | 3 | $46 |
| Bayer | 3 | $43 |
| Amgen | 2 | $33 |
| GSK | 1 | $18 |
| Impulse Dynamics (USA) Inc. | 1 | $17 |
| United Therapeutics Corporation | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $14 |
| Cordis US CORP. | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RUBY Coil$854
- TurboHawk$578
- Indigo System$259
- HawkOne$223
- Navicross$120
- Misago$120
- GlideWire$120
- Penumbra System$119
- SYMPLICITY G3$114
How this compares
$5,687 in reported general payments places this provider in the 60th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 308 | $288,313 |
| FarxigaDapagliflozin Propanediol | 235 | $242,957 |
| EntrestoSacubitril/Valsartan | 179 | $197,491 |
| BrilintaTicagrelor | 255 | $178,927 |
| XareltoRivaroxaban | 61 | $67,274 |
| VerquvoVericiguat | 21 | $16,782 |
| JardianceEmpagliflozin | 24 | $14,945 |
| JanuviaSitagliptin Phosphate | 39 | $13,739 |
| Metoprolol Succinate | 442 | $7,651 |
| Nifedipine ErNifedipine | 218 | $6,306 |
| Irbesartan | 226 | $4,676 |
| Potassium Chloride | 185 | $3,977 |
| Metolazone | 64 | $3,289 |
| Cilostazol | 122 | $3,164 |
| Sildenafil Citrate | 13 | $3,148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $266 | $421,884490 claims |
| NovartisEntresto | $60 | $197,491179 claims |
| Johnson & JohnsonXarelto | $59 | $67,27461 claims |
| MerckVerquvo, Januvia | $185 | $30,52260 claims |
| Boehringer IngelheimJardiance | $46 | $14,94524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Greenville
- Dharmesh PatelSouthaven$1.5M
- Barry BertoletTupelo$469K
- Donny StokesJackson$207K
- Mahmoud ZayedPascagoula$103K
- James BenslerJackson$64K
- Michael HallJackson$54K
- Hugo QuintanaPascagoula$48K
- Ediz TasanPascagoula$42K
- Lawrence LeaderHattiesburg$40K
- Matthew HannKeesler Afb$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.